Loading...

LakeShore Biopharma Co., Ltd

LSB•NASDAQ
Healthcare
Biotechnology
$1.07
$-0.12(-10.08%)

LakeShore Biopharma Co., Ltd (LSB) Stock Overview

Explore LakeShore Biopharma Co., Ltd’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.8/100

Key Financials

Market Cap19.8M
P/E Ratio-0.41
EPS (TTM)$-2.90
ROE-0.49%
Fundamental Analysis

AI Price Forecasts

1 Week$1.01
1 Month$-1.50
3 Months$0.96
1 Year Target$0.71

LSB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of LakeShore Biopharma Co., Ltd (LSB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 47.83, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.71.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.41 and a market capitalization of 19.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

47.83RSI (14)
0.01MACD
39.83ADX
Revenue Growth
-16.56%
↓ 16.56%
Profit Growth
$-17.61
↓ 197.96%
EPS Growth
$-17.61
↓ 115.43%
Operating Margin
-87.20%
↓ 219.86%
ROE
-49.36%
↓ 197.96%
Dividend Yield
0.00%
Analyst Recommendations data is not available for LSBAnalyst Recommendations details for LSB are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

CEO

Wang Xu

Employees

758

Headquarters

Building No. 2, Beijing

Founded

2021

Frequently Asked Questions

;